ACADIA PHARMACEUTICALS INC
ACAD evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $4.73B
- Lead Asset:
- acp-2591 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ACAD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACAD
ACADIA Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on neurological and rare disease therapies, with two marketed products (NUPLAZID and DAYBUE) and a pipeline centered on remlifanserin for Alzheimer's disease psychosis.
Key risk: Share price decline
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 47 clinical trials · 2 catalysts · 4 FDA decisions for ACADIA PHARMACEUTICALS INC.
ACADIA Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on neurological and rare disease therapies, with two marketed products (NUPLAZID and DAYBUE) and a pipeline centered on remlifanserin for Alzheimer's disease psychosis.
- Cash & equivalents of $385.0M as of 2026-06-30 [sec].
- Total revenue of $308.0M as of 2026-06-30 [sec].
- Net income of $31.5M as of 2026-06-30 [sec].
- Shareholders' equity of $1,306.6M as of 2026-06-30 [sec].
- Projected combined net sales of approximately $1.7 billion in 2028, including ~$1 billion for NUPLAZID and ~$700 million for DAYBUE [news · 2026-01-13].
What works
- Two approved commercial products (NUPLAZID and DAYBUE) generating revenue and providing a foundation for growth [news · 2026-08-12].
- Strong cash position of $385.0M as of 2026-06-30 provides financial flexibility for pipeline development and commercial expansion [sec].
- Patent protection for trofinetide (DAYBUE) extended to 2041, securing long-term exclusivity for the Rett syndrome therapy [news · 2026-10-06].
What to weigh
- Share price has declined significantly, with a 30-day return down 28.23% and year-to-date return down 23.51% as of 2026-10-06 [news · 2026-10-06].
- Pipeline is heavily dependent on remlifanserin for Alzheimer's disease psychosis, a high-risk, late-stage development program with no approved precedent [news · 2026-05-19].
- DAYBUE faces competition from multiple Rett syndrome therapies in development, including gene therapy and other small molecules [pipeline].
From the filings
Quoted directly from source documents.
Patent protection for trofinetide extended to 2041
“a fresh USPTO Notice of Allowance extending potential trofinetide protection to 2041”
News · October 6, 2026
Catalyst timeline
- 2038-08-27 · Patent_Expiry · PIMAVANSERIN TARTRATE — Patent expiry for NUPLAZID (pimavanserin tartrate) under NDA210793.
- 2042-07-12 · Patent_Expiry · TROFINETIDE — Patent expiry for DAYBUE (trofinetide) under NDA219884.
Risks & what to watch (3)›
Key risks
- Share price decline — 30-day share price return down 28.23% and year-to-date down 23.51% as of 2026-10-06 [news · 2026-10-06].
- Pipeline concentration risk — Heavy reliance on remlifanserin for Alzheimer's disease psychosis, a high-risk program with no approved precedent [news · 2026-05-19].
- Competitive pressure on DAYBUE — Multiple Rett syndrome therapies in development, including gene therapy and other small molecules [pipeline].
What to watch
- Top-line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis, expected between August and October 2026 [news · 2026-01-13].
- Commercial expansion of NUPLAZID and DAYBUE, including the launch of DAYBUE STIX in 2026 [news · 2026-01-13].
- Patent expiry for pimavanserin tartrate (NUPLAZID) on 2038-08-27 [catalyst].
- Patent expiry for trofinetide (DAYBUE) on 2042-07-12 [catalyst].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run ACADIA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACADIA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.33 · 1% dilution
Lead: Approved
6 candidates
2 upcoming, next in ~4335d
0 buys · 9 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
339
Total value held
$3.63B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 42,896,690 | $954.9M |
| blackrock, inc. | 21,550,921 | $479.7M |
| vanguard portfolio management llc | 8,671,645 | $193.0M |
| state street corp | 8,332,771 | $185.5M |
| rtw investments, lp | 7,144,524 | $159.0M |
| vanguard capital management llc | 5,661,400 | $126.0M |
| geode capital management, llc | 3,464,689 | $77.1M |
| first trust advisors lp | 3,343,868 | $74.4M |
| dimensional fund advisors lp | 3,155,160 | $70.2M |
| palo alto investors lp | 2,872,695 | $63.9M |
Showing top 10 of 339 institutional holders of ACADIA PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 10.3%
- Days to cover
- 6.4
- Shares short
- 11,156,379
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACAD short interestGovernance
Frequently asked questions
What is the AI investment thesis for ACADIA PHARMACEUTICALS INC?
ACADIA Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on neurological and rare disease therapies, with two marketed products (NUPLAZID and DAYBUE) and a pipeline centered on remlifanserin for Alzheimer's disease psychosis.
What is ACADIA PHARMACEUTICALS INC's lead drug candidate?
ACADIA PHARMACEUTICALS INC's most advanced tracked candidate is acp-2591 (Phase 2) for Rett syndrome and Fragile X syndrome.
What is ACADIA PHARMACEUTICALS INC's next catalyst?
ACADIA PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210793" — expected August 27, 2038.
Who is the CEO of ACADIA PHARMACEUTICALS INC?
Ms. Catherine E. Owen Adams is the chief executive officer of ACADIA PHARMACEUTICALS INC (ACAD).
Where is ACADIA PHARMACEUTICALS INC headquartered?
ACADIA PHARMACEUTICALS INC (ACAD) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.